Lilly and Alzheimer’s Disease International Partner to Address Barriers that Impact the Accurate and Timely Diagnosis of Alzheimer’s Disease

INDIANAPOLIS, June 12, 2014 /PRNewswire/ — Eli Lilly and Company and Alzheimer’s Disease International (ADI) today announced the availability of educational resources intended to help improve communication between patients, caregivers and their physicians to ensure physicians have information to accurately diagnose the cause of the patient’s cognitive impairment – whether that be Alzheimer’s disease, another form of dementia, or some other cause. The availability of resources occurs as two meetings take place in the United Kingdom (UK) to address related aspects of Alzheimer’s disease, specifically the need for care innovation and the future financial burden of the disease. The meetings are a result of the G8 Dementia Summit held in December 2013.

Logo – http://photos.prnewswire.com/prnh/20031219/LLYLOGO [ http://photos.prnewswire.com/prnh/20031219/LLYLOGO ]

In 2012, Adelphi Research conducted The International Alzheimer’s Disease Physician Survey, on behalf of Lilly, revealing physician-perceived barriers that impact their ability to make formal Alzheimer’s disease diagnoses, citing lack of communication between patients and caregivers and physicians as one of the most common challenges. In fact, 40 percent of respondents reported that patients and caregivers did not provide enough information to help them make a formal diagnosis. Furthermore, the survey confirmed when diagnoses are made, physicians believe they are often made too late in the progression of the illness for physicians to intervene in a meaningful way.

Continue reading….

Advertisements